Mobile cone-beam computed tomography combined with electromagnetic navigation bronchoscopy for the diagnosis of peripheral pulmonary nodules.

PulmonologySep 10, 2026 (epub)
Clinical ResearchPulmonologyRadiology (Diagnostic)

Lin Ye, Siyuan Hong, Xiaoxuan Zheng et al.

✦ AI-curated · Sources linked

In 30 seconds

This prospective, single-centre trial assessed the diagnostic performance of mobile cone-beam computed tomography (mCBCT) combined with electromagnetic navigation bronchoscopy (ENB) for peripheral pulmonary nodules (PPNs). The study found an overall diagnostic yield of 79.6%. mCBCT-guided navigation correction significantly improved the tool-in-lesion rate from 54.6% to 87.0%, an absolute increase of 32.4%.

Key findings

  • Overall diagnostic yield was 79.6% (86/108) after mCBCT assessment.
  • Tool-in-lesion rate improved from 54.6% (59/108) to 87.0% (94/108) after navigation correction.
  • Navigation correction was required in 42.6% (46/108) of cases.
  • Procedure-related atelectasis was identified in 7.4% (8/108) of patients.

Why it matters

The integration of mCBCT with ENB enhances the diagnostic yield for peripheral pulmonary nodules, particularly for smaller lesions and those lacking a CT bronchus sign, which may improve patient outcomes through more accurate diagnoses.

Source

PubMed · PMID 42717748

Published in Pulmonology. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pulmonology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.